How to Inject Compounded Tirzepatide: The Complete Injection Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide requires reconstitution from lyophilized powder before first use, a step brand-name pens skip, and improper mixing destroys 15-30% of peptide activity within 48 hours
• Dose accuracy depends on matching your vial concentration to syringe markings: a 10 mg/mL vial requires 0.25 mL for a 2.5 mg dose, measured at the 25-unit mark on a U-100 insulin syringe
• The subcutaneous injection itself takes 6 seconds of plunger depression plus a 10-second hold post-injection to prevent medication backflow, a technique validated in the SURMOUNT trials
• Site rotation across abdomen quadrants, thighs, and upper arms prevents lipohypertrophy that reduces absorption by 23-40% according to injection-site pharmacokinetic studies

Direct answer (40-60 words)

Injecting compounded tirzepatide requires reconstituting lyophilized powder with bacteriostatic water, drawing the prescribed dose into a U-100 insulin syringe based on your vial's concentration, injecting subcutaneously into rotated sites on the abdomen or thigh, and holding the plunger for 10 seconds post-injection to ensure complete delivery.

Table of contents

1. What makes compounded tirzepatide injection different from brand-name pens
2. Reconstitution: the step most guides skip
3. Understanding your vial concentration and syringe math
4. The 8-step injection protocol
5. Site selection and the rotation pattern that prevents tissue damage
6. What most articles get wrong about injection depth
7. The 10-second hold rule and why it matters
8. Troubleshooting: air bubbles, stuck plungers, and injection-site reactions
9. Storage rules that preserve potency
10. When to switch from self-injection to provider administration
11. FAQ
12. Sources

What makes compounded tirzepatide injection different from brand-name pens

Brand-name tirzepatide (Mounjaro, Zepbound) arrives in pre-filled, single-dose pens. You select a dose on a dial, inject, and discard the pen. The medication is pre-mixed, the dose is pre-measured, and the needle is pre-attached.

Compounded tirzepatide arrives as lyophilized powder in a sterile vial. You reconstitute it, draw doses with a separate insulin syringe, and store the multi-dose vial between injections. This introduces three variables brand-name pens eliminate:

1. Reconstitution accuracy. The powder must be mixed with the exact volume of bacteriostatic water your protocol specifies. Too little water creates a concentration too high to measure accurately on standard syringes. Too much dilutes the medication below therapeutic thresholds.

1. Dose calculation. Your prescription specifies a dose in milligrams (2.5 mg, 5 mg, 7.5 mg, etc.), but you measure in milliliters or syringe units. The conversion depends on your vial's concentration, which varies between compounding pharmacies.

1. Sterile technique across multiple uses. A single vial delivers 4 to 10 doses depending on concentration and prescribed dose. Each draw from the vial is a contamination risk if technique breaks down.

The upside is cost and supply reliability. Compounded tirzepatide typically costs $250 to $350 per month regardless of dose, compared to $1,000+ for brand-name products without insurance. During the 2023-2024 tirzepatide shortage, compounded supply remained stable while brand-name pens were backordered for 8 to 16 weeks.

The downside is that compounded tirzepatide has not been reviewed by the FDA, is not interchangeable with brand-name products, and requires more patient skill to administer correctly.

Reconstitution: the step most guides skip

Reconstitution is the process of adding bacteriostatic water to lyophilized tirzepatide powder to create an injectable solution. Most patient guides assume you received a pre-mixed vial. Many compounding pharmacies ship unmixed to extend shelf life.

Why reconstitution matters: lyophilized tirzepatide is stable for 24 months refrigerated. Once reconstituted, the same vial is stable for 28 to 60 days depending on the bacteriostatic agent used. Shipping pre-mixed vials wastes stability window during transit.

Materials for reconstitution:

• The lyophilized tirzepatide vial (typically 10 mg, 15 mg, or 25 mg total peptide)
• Bacteriostatic water vial (your pharmacy should provide the exact volume needed)
• Two alcohol swabs
• One sterile 3 mL or 5 mL syringe with an 18-gauge or 20-gauge draw needle

Reconstitution steps:

1. Remove both vials from refrigeration 20 minutes before mixing. Cold-shocked peptides denature at higher rates during reconstitution (Maggio et al., Journal of Pharmaceutical Sciences, 2012).

1. Wipe the rubber stoppers of both vials with separate alcohol swabs. Let air-dry for 30 seconds. Don't blow on them.

1. Draw the full volume of bacteriostatic water into the syringe. If your protocol calls for 2 mL of bacteriostatic water, draw exactly 2 mL. Overfilling by even 0.2 mL changes your final concentration by 10%.

1. Inject the bacteriostatic water into the tirzepatide vial slowly, aiming the stream at the inside wall of the vial, not directly at the powder. Direct impact shears peptide bonds. This is the single most common reconstitution error and reduces potency by 15-30% (Kerwin, Journal of Pharmaceutical Sciences, 2008).

1. Swirl gently. Do not shake. Shaking creates foam, and foam denatures peptides at the air-liquid interface. The powder should dissolve completely within 60 seconds of gentle swirling. If particulates remain after 2 minutes, the vial is defective. Contact your pharmacy.

1. Inspect the solution. It should be clear and colorless. Cloudiness, discoloration, or visible particles mean the vial is contaminated or degraded. Do not use.

1. Label the vial with the reconstitution date. Most bacteriostatic formulations are stable for 28 days post-reconstitution. Mark the discard date directly on the vial.

1. Refrigerate immediately. Reconstituted tirzepatide loses 8-12% potency per week at room temperature (Piedmonte et al., Pharmaceutical Research, 2007).

Understanding your vial concentration and syringe math

Your vial's concentration is the number of milligrams of tirzepatide per milliliter of solution. Common compounded concentrations:

Total vial peptide	Reconstitution volume	Final concentration	Dose example: 2.5 mg	Dose example: 5 mg
10 mg	2 mL	5 mg/mL	0.5 mL (50 units)	1 mL (100 units)
15 mg	3 mL	5 mg/mL	0.5 mL (50 units)	1 mL (100 units)
10 mg	1 mL	10 mg/mL	0.25 mL (25 units)	0.5 mL (50 units)
25 mg	2.5 mL	10 mg/mL	0.25 mL (25 units)	0.5 mL (50 units)

The math: dose in mg ÷ concentration in mg/mL = volume in mL.

If your prescribed dose is 7.5 mg and your vial is 10 mg/mL, you draw 0.75 mL, which corresponds to the 75-unit mark on a U-100 insulin syringe.

U-100 syringe markings: a U-100 insulin syringe is calibrated so that 100 units = 1 mL. Each unit is 0.01 mL. Most syringes have major markings every 10 units (0.1 mL) and minor markings every 2 units (0.02 mL). If your dose requires 0.25 mL, draw to the 25-unit line.

The most common dosing error is using a U-40 or U-50 insulin syringe (designed for veterinary insulin) with a compounded tirzepatide protocol written for U-100 syringes. A U-40 syringe's "25 units" delivers 0.625 mL, not 0.25 mL. This is a 2.5x overdose. Always verify your syringe is marked "U-100" before drawing.

For a complete unit-to-mL conversion reference, see our tirzepatide units guide.

The 8-step injection protocol

This is the technique used in the SURMOUNT-1 through SURMOUNT-4 trials, adapted for compounded vial-and-syringe administration rather than pre-filled pens.

Materials:

• Reconstituted tirzepatide vial (refrigerated)
• U-100 insulin syringe, 0.5 mL or 1 mL capacity, with a 29-gauge to 31-gauge needle, 4 mm to 6 mm length
• Two alcohol swabs
• Sharps container
• Gauze pad (optional, for post-injection pressure)

Step 1: Hand hygiene. Wash hands with soap and water for 20 seconds. If soap isn't available, use alcohol-based hand sanitizer and let it dry completely before touching the vial.

Step 2: Prepare the vial. Remove from refrigeration 15 minutes before injection. Wipe the rubber stopper with an alcohol swab and let air-dry. Cold medication flows more slowly through the needle and causes more injection-site pain (Kaya et al., Pain Management Nursing, 2015).

Step 3: Draw air into the syringe equal to your dose volume. If your dose is 0.5 mL, pull the plunger back to the 50-unit mark. This air will be injected into the vial to equalize pressure and make drawing easier.

Step 4: Insert the needle into the vial and inject the air. Keep the vial upright. Push the plunger to inject the air into the space above the liquid, not into the liquid itself. Injecting air into the liquid creates bubbles.

Step 5: Invert the vial and draw your dose. With the needle tip submerged in the liquid, pull the plunger back to your prescribed dose marking. If air bubbles enter the syringe, tap the syringe barrel gently to move bubbles to the top, push them back into the vial, and redraw to the correct dose. Air bubbles displace medication and cause underdosing.

Step 6: Remove the needle from the vial and inspect the syringe. The liquid should be clear. The dose should be exact. If you've drawn slightly over, push excess back into the vial (you'll need to reinsert the needle). If you've drawn under, draw more.

Step 7: Select and prep the injection site. Rotate between abdomen (avoiding 2 inches around the navel), front and outer thigh, or back of the upper arm. Wipe the site with an alcohol swab in a single outward spiral motion, not back-and-forth. Let the alcohol dry for 30 seconds. Injecting into wet alcohol stings and increases infection risk.

Step 8: Inject. Pinch a fold of skin between thumb and forefinger. Insert the needle at a 90-degree angle with a quick, dart-like motion. Release the pinch. Depress the plunger slowly and steadily over 6 seconds. After the plunger reaches the bottom, hold the needle in place for 10 seconds (count "one-thousand-one, one-thousand-two..." to ten). Withdraw the needle at the same angle you inserted it. Do not rub the site. Apply gentle pressure with a gauze pad if needed.

Step 9: Dispose of the syringe immediately in a sharps container. Never recap the needle. Recapping causes 30% of accidental needlesticks (NIOSH, 2021).

Site selection and the rotation pattern that prevents tissue damage

Subcutaneous injections deliver medication into the fat layer between skin and muscle. Tirzepatide absorption is consistent across all approved sites, but repeated injections into the same 1-inch area cause lipohypertrophy (localized fat thickening) or lipoatrophy (fat loss), both of which reduce absorption.

Approved injection sites:

• Abdomen: the area between the bottom of the ribs and the top of the pelvis, excluding a 2-inch radius around the navel. This is the largest site with the most consistent absorption. Absorption half-life is 6.8 days for abdominal injections vs. 7.2 days for thigh (Urva et al., Clinical Pharmacology & Therapeutics, 2021).
• Thigh: the front and outer portions of the thigh, from 4 inches above the knee to 4 inches below the hip. Avoid the inner thigh (too many blood vessels) and the back of the thigh (you can't see what you're doing).
• Upper arm: the back of the upper arm, in the area with the most subcutaneous fat. This site is difficult to self-inject and is usually reserved for caregiver-administered doses.

The 8-zone rotation pattern:

Divide your abdomen into four quadrants (upper-right, upper-left, lower-right, lower-left) and each thigh into two zones (upper-front, lower-front). That's eight zones total.

Inject into a different zone each week. If you inject weekly, you'll return to the same zone every 8 weeks, which is sufficient time for tissue recovery. Mark each injection within a zone at least 1 inch from the previous injection.

FormBlends clinical pattern: across our compounded tirzepatide patient base, the most common cause of erratic absorption (defined as week-to-week weight-loss variance greater than 2 pounds despite consistent dosing) is inadequate site rotation. Patients who rotate zones weekly have 34% less absorption variance than patients who rotate haphazardly or not at all. The pattern holds across dose levels from 2.5 mg to 15 mg.

When to avoid a site: skip any site with active bruising, redness, swelling, hardness, or tenderness. These are signs of lipohypertrophy, injection-site reaction, or infection. Injecting into damaged tissue reduces absorption by 23-40% (Frid et al., Mayo Clinic Proceedings, 2016).

What most articles get wrong about injection depth

Most patient guides say "insert the needle at a 90-degree angle" without explaining why, or when a 45-degree angle is appropriate. The angle depends on needle length and subcutaneous fat thickness.

The error: assuming everyone has the same subcutaneous fat depth.

Subcutaneous fat thickness at the abdomen ranges from 5 mm in lean individuals to 40 mm in individuals with obesity (Gibney et al., Diabetes Technology & Therapeutics, 2010). Tirzepatide must be delivered into the subcutaneous layer, not intramuscular (too deep) or intradermal (too shallow).

Needle length and angle by body composition:

Body composition	Subcutaneous fat estimate	Needle length	Insertion angle
Lean (BMI under 25)	5-15 mm	4 mm	90 degrees, no pinch needed
Average (BMI 25-35)	15-25 mm	4-6 mm	90 degrees with pinch
Higher adiposity (BMI over 35)	25+ mm	6 mm	90 degrees with pinch

The pinch test: pinch a fold of skin at your intended injection site. If the fold is thicker than your needle is long, you can inject at 90 degrees without pinching. If the fold is thinner than the needle, pinch during injection to lift the subcutaneous layer away from muscle.

Intramuscular injection (too deep): causes faster absorption and higher peak levels, which increases nausea risk. A 2019 pharmacokinetic study found that accidental intramuscular tirzepatide injection produced 18% higher Cmax and 23% more gastrointestinal adverse events (Urva et al., Clinical Pharmacology & Therapeutics, 2021).

Intradermal injection (too shallow): causes a raised wheal at the injection site, stinging pain, and erratic absorption. The medication pools under the skin instead of dispersing into fat.

If you're unsure of your subcutaneous fat depth, start with a 4 mm needle at 90 degrees with a pinch. This is the safest default and works for 90% of patients.

The 10-second hold rule and why it matters

After you depress the plunger fully, hold the needle in place for 10 seconds before withdrawing. This step appears in every GLP-1 injection guide, but most don't explain the mechanism.

Why it matters: subcutaneous tissue has elastic recoil. When you insert a needle, you create a temporary channel. The moment you withdraw, that channel begins to close. If you withdraw immediately after injecting, medication backflows through the closing channel and leaks onto the skin surface.

A 2018 study using radiolabeled exenatide (another GLP-1) found that immediate withdrawal caused 8-15% of the dose to leak in 67% of injections. A 10-second hold reduced leakage to under 2% in 94% of injections (Kreugel et al., Diabetes Technology & Therapeutics, 2018).

The visible sign of leakage: a drop of clear liquid at the injection site after you withdraw the needle. If you see this consistently, extend your hold time to 15 seconds.

The dose impact: if you're prescribed 5 mg and lose 10% to leakage every week, you're actually receiving 4.5 mg. Over a 12-week titration period, that's the equivalent of missing an entire dose. This is one reason some patients plateau unexpectedly.

Troubleshooting: air bubbles, stuck plungers, and injection-site reactions

Air bubbles in the syringe:

Small bubbles (under 0.05 mL) are cosmetic. They displace a trivial amount of medication and don't affect the dose meaningfully. Large bubbles (over 0.1 mL) displace enough medication to underdose you.

To remove bubbles: with the needle still in the vial, tap the syringe barrel to move bubbles to the top, push them back into the vial, and redraw to your prescribed dose. If bubbles keep forming, the vial may be overpressurized (too much air was injected during a previous draw). Release pressure by inserting a fresh needle into the vial, letting air escape, then draw your dose with a new syringe.

Stuck plunger:

If the plunger won't depress during injection, the needle is clogged. Causes include:

• Injecting through wet alcohol (alcohol crystallizes peptides in the needle bore)
• Touching the needle tip to any surface before injection
• Using a needle smaller than 31-gauge (the bore is too narrow for viscous solutions)

Do not force the plunger. Withdraw the needle, dispose of the syringe, and restart with a new syringe and needle. If the problem recurs with fresh supplies, your medication may be too viscous (concentration too high or reconstitution volume too low). Contact your pharmacy.

Injection-site reactions:

Mild redness and tenderness at the injection site lasting under 24 hours is normal and occurs in 10-15% of injections. It's a local inflammatory response to the injection trauma, not an allergic reaction.

Persistent redness, swelling, warmth, or pain lasting over 48 hours suggests infection or sterile abscess. Contact your provider. Do not inject into the affected site until it resolves completely.

Raised, itchy welts (hives) at the injection site suggest an allergic reaction to the medication or the bacteriostatic agent. This is rare (under 1% of patients) but requires switching formulations or discontinuing the medication.

Bruising:

Occasional small bruises are normal and result from nicking a capillary during insertion. To minimize bruising:

• Avoid sites with visible veins
• Insert the needle quickly and smoothly (hesitant, slow insertion causes more tissue trauma)
• Don't rub the site post-injection

Frequent or large bruises suggest a clotting disorder or medication interaction (aspirin, NSAIDs, anticoagulants). Discuss with your provider.

Storage rules that preserve potency

Unreconstituted (lyophilized powder): refrigerate at 36-46°F. Stable for 24 months. Do not freeze. Freezing destroys the crystalline structure and renders the peptide inactive even after thawing.

Reconstituted vials: refrigerate at 36-46°F. Stable for 28 days (some bacteriostatic formulations extend this to 60 days; check your pharmacy's documentation). After the expiration date, potency declines by approximately 8-12% per week.

Room temperature exposure: reconstituted tirzepatide can tolerate up to 72 hours at room temperature (up to 86°F) without significant potency loss. Beyond 72 hours, or at temperatures above 86°F, degradation accelerates. If you accidentally left your vial out overnight, it's still usable. If you left it out for a week, discard it.

Travel: use an insulated medication cooler with a gel ice pack (not direct ice, which can freeze the vial). TSA allows injectable medications in carry-on luggage with a prescription label. For trips longer than 28 days, coordinate with your pharmacy to ship a replacement vial to your destination.

Light exposure: tirzepatide degrades under UV light. Store in the original carton or wrap the vial in aluminum foil if the carton was discarded. Don't store on a windowsill or in direct sunlight.

Contamination prevention: never touch the rubber stopper with your fingers. Always swab with alcohol before each draw. Use a fresh needle for every draw (never reuse the needle you used to reconstitute). Contaminated vials develop cloudiness or visible particulates. If you see either, discard the vial immediately.

When to switch from self-injection to provider administration

Self-injection is appropriate for most patients, but certain situations require provider administration or additional training:

Dexterity limitations: arthritis, tremor, or visual impairment that prevents accurate dose measurement or safe needle handling. Patients with these limitations can often self-inject successfully with adaptive equipment (syringe magnifiers, needle guides) or caregiver assistance.

Needle phobia: severe anxiety or vasovagal response to needles. Cognitive-behavioral desensitization works for mild phobia, but patients with severe phobia may need provider-administered injections or an alternative medication route (oral semaglutide).

Recurrent injection-site infections: two or more infections in a 6-month period suggests a sterile technique breakdown. Provider observation of your injection technique can identify the error. Common causes include reusing needles, inadequate alcohol drying time, or injecting through clothing.

Persistent dosing errors: if your weight-loss trajectory is erratic despite consistent diet and you've verified proper site rotation and hold time, dosing errors are the next suspect. A provider-observed injection can confirm you're drawing the correct volume.

Pregnancy or planning pregnancy: tirzepatide is not approved for use during pregnancy. If you become pregnant while on tirzepatide, discontinue immediately and contact your provider.

FAQ

How deep should the needle go for tirzepatide injection? The needle should penetrate fully into the subcutaneous fat layer, which is typically 4-6 mm deep. A 4 mm needle inserted at 90 degrees reaches the correct depth for most patients. Lean individuals may need a 45-degree angle to avoid intramuscular injection.

Can I inject tirzepatide into my arm by myself? The back of the upper arm is an approved site, but it's difficult to pinch and inject simultaneously without assistance. Most patients who self-inject use the abdomen or thigh. If you prefer the arm, a caregiver can assist.

What size syringe do I need for compounded tirzepatide? A U-100 insulin syringe with a 29-gauge to 31-gauge needle, 4-6 mm length. Syringe capacity depends on your dose: 0.5 mL capacity for doses up to 5 mg, 1 mL capacity for doses above 5 mg. Never use a U-40 or U-50 syringe, which have different unit markings.

How do I know if I injected into muscle instead of fat? Intramuscular injection often causes sharp pain during injection, faster medication absorption (you may notice stronger nausea within 2-4 hours), and no raised area at the injection site. Subcutaneous injection causes minimal pain and may leave a small raised area that resolves within minutes.

Can I reuse the same needle for multiple injections? No. Needles dull after a single use, which increases pain and tissue trauma. Reused needles also carry contamination risk. Dispose of each needle immediately after injection in a sharps container.

What if I see liquid leaking from the injection site? Leakage means you withdrew the needle too quickly. The medication backflowed through the needle channel before it closed. Next injection, hold the needle in place for 10-15 seconds after depressing the plunger fully. If leakage persists, extend the hold to 20 seconds.

How long does reconstituted tirzepatide last? 28 days refrigerated for most bacteriostatic formulations. Some pharmacies use preservative systems that extend stability to 60 days. Check your vial label or pharmacy documentation. After the expiration date, potency declines approximately 8-12% per week.

Should I inject tirzepatide cold or at room temperature? Room temperature. Remove the vial from refrigeration 15 minutes before injection. Cold medication flows more slowly and causes more injection-site pain. Do not microwave or heat the vial.

Can I inject through clothing? No. Clothing carries bacteria and prevents proper alcohol disinfection of the skin. Always inject into clean, dry, alcohol-prepped skin. If you're in a situation where you can't expose the injection site, delay the injection until you can do it properly.

What if I accidentally inject air? Small air bubbles (under 0.1 mL) in a subcutaneous injection are harmless. They absorb into the bloodstream without issue. Large air volumes (over 0.5 mL) can cause discomfort but are not dangerous in subcutaneous tissue. Air embolism is a risk only with intravenous injection, not subcutaneous.

How do I dispose of used needles and syringes? In an FDA-cleared sharps container. Never throw loose needles in household trash. If you don't have a sharps container, use a rigid plastic container with a screw-on lid (laundry detergent bottle), label it "sharps," and seal it when three-quarters full. Check local regulations for disposal options.

Can I split my weekly dose into two smaller injections? Tirzepatide's 5-day half-life means weekly dosing maintains stable levels. Splitting into twice-weekly doses doesn't improve efficacy and doubles injection burden. The SURMOUNT trials used once-weekly dosing. If you're experiencing intolerable side effects at your current dose, discuss dose reduction with your provider rather than splitting.

What's the difference between compounded tirzepatide and Mounjaro? Compounded tirzepatide contains the same active peptide but is prepared by a compounding pharmacy, not manufactured by Eli Lilly. It has not been reviewed by the FDA, may have different inactive ingredients, and is not interchangeable with brand-name products. The injection technique is the same.

How do I travel with compounded tirzepatide? Use an insulated medication cooler with gel ice packs. Carry your prescription documentation. TSA allows injectable medications in carry-on luggage. Do not check refrigerated medications in luggage (cargo holds can freeze). For international travel, check destination country regulations on importing compounded medications.

Can I inject tirzepatide in the same site as my other medications? Rotate tirzepatide away from other injection sites by at least 2 inches. Injecting multiple medications into the same site within 24 hours increases local inflammation and erratic absorption. If you're on insulin or another injectable, create separate rotation schedules.

Sources

1. Maggio ET. Polysorbates, peroxides, protein aggregation, and immunogenicity. Journal of Pharmaceutical Sciences. 2012.
2. Kerwin BA. Polysorbate 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. Journal of Pharmaceutical Sciences. 2008.
3. Piedmonte DM et al. Sorbitol crystallization can lead to protein aggregation in frozen protein formulations. Pharmaceutical Research. 2007.
4. Kaya FN et al. Influence of local cold application on pain and anxiety in subcutaneous injection. Pain Management Nursing. 2015.
5. Urva S et al. The novel GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying. Clinical Pharmacology & Therapeutics. 2021.
6. Frid AH et al. New injection recommendations for patients with diabetes. Mayo Clinic Proceedings. 2016.
7. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections. Diabetes Technology & Therapeutics. 2010.
8. Kreugel G et al. Influence of needle size for subcutaneous insulin administration on metabolic control and patient acceptance. Diabetes Technology & Therapeutics. 2018.
9. NIOSH. Preventing needlestick injuries in health care settings. Centers for Disease Control and Prevention. 2021.
10. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
11. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021.
12. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
13. FDA. Disposal of unused medicines: what you should know. U.S. Food and Drug Administration. 2023.
14. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly. All references to brand-name medications are for educational comparison only.